Boston Scientific Neuromodulation Corp

Boston Scientific Neuromodulation Corp, a subsidiary of Boston Scientific Corporation, supplies neuromodulation and pain management medical devices—including spinal cord stimulation systems, implantable pain pumps, and radiofrequency ablation equipment—to the Department of Defense and Department of Veterans Affairs as a prime contractor competing on a full-and-open basis. The company operates as a for-profit manufacturer of goods headquartered in Valencia, California, as a child entity of Boston Scientific Corp, a Marlborough, Massachusetts–based global medical technology company.

Boston Scientific Neuromodulation's federal footprint is dominated by a single vehicle: the SPE2DE indefinite delivery contract valued at $83.1 million with the Defense Logistics Agency Troop Support Medical branch, awarded August 17, 2021, and running through August 16, 2026. This contract serves as the foundation for the company's federal work. The source data spanning 1999 through May 2026 records 1,569 prime awards with combined potential value of $204.3 million, of which $24.8 million has been obligated. Activity has remained steady at roughly 94 to 134 awards per year over the past five years, with 17 awards recorded year-to-date through May 2026. The company does not compete under set-asides and holds no subcontract positions in the source data.

The Defense Logistics Agency Troop Support Medical branch dominates customer concentration, accounting for 521 awards (48% of the total award count) and $174.5 million in combined potential value (85% of all potential dollars). The next largest customers—the Department of the Army Medical Command (94 awards, $16.8 million), the Department of the Navy Bureau of Medicine and Surgery (84 awards, $3.1 million), and the Department of the Air Force Materiel Command (28 awards, $781 thousand)—together account for only 11% of potential value. The top five customers represent 96% of combined potential value, signaling acute customer concentration risk. The SPE2DE vehicle alone carries 519 delivery orders worth $8.3 million in combined potential value. Secondary vehicles include the V791P0340 indefinite delivery contract (289 task orders, $932 thousand), the W81K0008A0027 IDC (25 task orders, $640 thousand), and the W81K0017A0014 BPA (7 task orders, $1.6 million).

Capability scope centers on non-opioid pain management solutions for military treatment facilities and VA medical centers, grounded in concrete awards including a $36,933.86 MRI-compatible system post-implant delivery order from Veterans Integrated Service Network 22 (April 2026), a $29,136.68 implant post purchase order from the same VISN (March 2026), and multiple recurring delivery orders for pain management devices, spinal cord stimulation systems (RestoreSensor and Spectra WaveWriter platforms), implantable pain pumps, radiofrequency ablation equipment, and associated accessories and technical support. The company's award portfolio spans medical, dental, and hospital equipment wholesale (636 awards), surgical appliance and supplies manufacturing (420 awards), and electromedical apparatus manufacturing (151 awards) under primary PSC codes Medical And Surgical Instruments, Equipment, And Supplies (920 awards) and Laboratory Equipment And Supplies (521 awards).

No recompete cliff details are provided in the source. All delivery orders observed carry fixed-price structures with economic price adjustment provisions and run two to three weeks from award to completion, indicating routine resupply patterns rather than strategic contract transitions. The parent company, Boston Scientific Corp, anchors broader federal presence across multiple therapeutic areas including cardiovascular, rhythm management, and interventional radiology devices, but this subsidiary's federal footprint is narrowly specialized in neuromodulation and pain management supply to defense health and VA systems.